2022年 論文

  • Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy.
    Hongo H, Kosaka T, Hayashi H, Nakamura K, Nishihara H, Mikami S, Beltran H, Oya M.
    Asian J Androl. 2022 Jan-Feb;24(1):116-118. doi: 10.4103/aja.aja_37_21.
  • Amiodarone-induced multiple organ damage in an Alström syndrome patient with end-stage renal disease and hepatic cirrhosis.
    Torimitsu T, Yoshida T, Nishi S, Itoh H, Oya M.
    CEN Case Rep. 2022 Feb;11(1):11-16. doi: 10.1007/s13730-021-00621-x. Epub 2021 Jul 5.
  • Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
    Yoshida T, Morimoto K, Kaburagi N, Fujino T, Takemitsu TY, Yamashita N, Oya M.
    Int Urol Nephrol. 2022 Apr;54(4):861-872. doi: 10.1007/s11255-021-02952-1. Epub 2021 Jul 15.
  • Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: Comparison with diagnostic cystoscopy.
    Kufukihara R, Kikuchi E, Shigeta K, Ogihara K, Arita Y, Akita H, Suzuki T, Abe T, Mizuno R, Jinzaki M, Oya M.
    Urol Oncol. 2022 Feb;40(2):61.e1-61.e8. doi: 10.1016/j.urolonc.2021.07.005. Epub 2021 Jul 29.
  • Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Arita Y, Akita H, Jinzaki M, Kikuchi E, Oya M.
    Urol Oncol. 2022 Mar;40(3):105.e19-105.e26. doi: 10.1016/j.urolonc.2021.07.029. Epub 2021 Aug 25.
  • The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
    Hagiwara M, Fushimi A, Matsumoto K, Oya M.
    Eur Urol. 2022 Feb;81(2):145-148. doi: 10.1016/j.eururo.2021.09.024. Epub 2021 Oct 6.
  • Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
    Yamashita R, Nakamura M, Okayama Y, Kawase M, Muraoka N, Fujita A, Notsu A, Asakura K, Hashizume A, Shinsaka H, Matsuzaki M, Niwakawa M, Oya M.
    Int J Urol. 2022 Mar;29(3):259-264. doi: 10.1111/iju.14760. Epub 2021 Dec 9.
  • Deep Learning Algorithm for Fully Automated Detection of Small (≤4 cm) Renal Cell Carcinoma in Contrast-Enhanced Computed Tomography Using a Multicenter Database.
    Toda N, Hashimoto M, Arita Y, Haque H, Akita H, Akashi T, Gobara H, Nishie A, Yakami M, Nakamoto A, Watadani T, Oya M, Jinzaki M.
    Invest Radiol. 2022 May 1;57(5):327-333. doi: 10.1097/RLI.0000000000000842.
  • Optimal surgical treatment for paratesticular leiomyosarcoma: retrospective analysis of 217 reported cases.
    Kamitani R, Matsumoto K, Takeda T, Mizuno R, Oya M.
    BMC Cancer. 2022 Jan 3;22(1):15. doi: 10.1186/s12885-021-09122-7.
  • Transient hypercalcemia in a patient with SAPHO syndrome.
    Yoshida T, Oya M.
    J Gen Fam Med. 2021 Jul 7;23(1):44-46. doi: 10.1002/jgf2.480. eCollection 2022 Jan.
  • First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.
    Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M.
    IJU Case Rep. 2021 Oct 20;5(1):41-44. doi: 10.1002/iju5.12383. eCollection 2022 Jan.
  • Outcomes of sorafenib treatment of advanced renal cell carcinoma according to IMDC risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib.
    Inamoto T, Azuma H, Adachi M, Okayama Y, Sunaya T, Oya M.
    Future Oncol. 2022 Apr;18(11):1371-1380. doi: 10.2217/fon-2021-1001. Epub 2022 Jan 13.
  • Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.
    Omura M, Kikuchi E, Shigeta K, Ogihara K, Hakozaki K, Hara S, Shirotake S, Ide H, Yoshimine S, Ohigashi T, Mizuno R, Oya M.
    Jpn J Clin Oncol. 2022 Apr 6;52(4):388-396. doi: 10.1093/jjco/hyab210.
  • MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.
    Hagiwara M, Fushimi A, Bhattacharya A, Yamashita N, Morimoto Y, Oya M, Withers HG, Hu Q, Liu T, Liu S, Wong KK, Long MD, Kufe D.
    Oncoimmunology. 2022 Feb 1;11(1):2029298. doi: 10.1080/2162402X.2022.2029298. eCollection 2022.
  • Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy.
    Mizuno R, Takamatsu K, Yasumizu Y, Tanaka N, Takeda T, Morita S, Matsumoto K, Kosaka T, Asanuma H, Mikami S, Oya M.
    Urol Int. 2022;106(11):1145-1149. doi: 10.1159/000521960. Epub 2022 Feb 9.
  • Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation.
    Baba Y, Kosaka T, Kobayashi H, Nakamura K, Mikami S, Nishihara H, Nakanishi M, Oya M.
    BMC Med Genomics. 2022 Feb 19;15(1):32. doi: 10.1186/s12920-022-01178-z.
  • An organ-derived extracellular matrix triggers in situ kidney regeneration in a preclinical model.
    Tajima K, Yagi H, Morisaku T, Nishi K, Kushige H, Kojima H, Higashi H, Kuroda K, Kitago M, Adachi S, Natsume T, Nishimura K, Oya M, Kitagawa Y.
    NPJ Regen Med. 2022 Feb 28;7(1):18. doi: 10.1038/s41536-022-00213-y.
  • Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.
    Arita Y, Akita H, Fujiwara H, Hashimoto M, Shigeta K, Kwee TC, Yoshida S, Kosaka T, Okuda S, Oya M, Jinzaki M.
    Eur J Radiol Open. 2022 Feb 15;9:100403. doi: 10.1016/j.ejro.2022.100403. eCollection 2022.
  • Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: A prospective survey.
    Sanjo T, Tanaka N, Shinojima T, Yasumizu Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M.
    Asian J Endosc Surg. 2022 Jul;15(3):585-590. doi: 10.1111/ases.13057. Epub 2022 Mar 20.
  • Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
    Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T, Kufukihara R, Shojo K, Mikami S, Shinojima T, Kakimi K, Tsunoda T, Aimono E, Nishihara H, Mizuno R, Oya M.
    J Immunother Cancer. 2022 Mar;10(3):e003883. doi: 10.1136/jitc-2021-003883.
  • Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation.
    Matsumoto S, Arita Y, Yoshida S, Fukushima H, Kimura K, Yamada I, Tanaka H, Yagi F, Yokoyama M, Matsuoka Y, Oya M, Tateishi U, Jinzaki M, Fujii Y.
    Abdom Radiol (NY). 2022 Jun;47(6):2178-2186. doi: 10.1007/s00261-022-03486-5. Epub 2022 Apr 15.
  • Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
    Oya M, Kaneko S, Imai T, Tsujino T, Sunaya T, Okayama Y.
    Cancer Chemother Pharmacol. 2022 Jun;89(6):761-772. doi: 10.1007/s00280-022-04428-0. Epub 2022 Apr 20.
  • Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study.
    Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, Kakehi Y, Naito S, Nonomura N, Ogawa O, Oya M, Suzuki K, Saito A, Uno S, Akaza H.
    BJUI Compass. 2021 Aug 20;3(1):26-36. doi: 10.1002/bco2.103. eCollection 2022 Jan.
  • Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
    Shigeta K, Matsumoto K, Tanaka N, Mikami S, Kosaka T, Yasumizu Y, Takeda T, Mizuno R, Kikuchi E, Oya M.
    Int J Mol Sci. 2022 May 5;23(9):5154. doi: 10.3390/ijms23095154.
  • Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.
    Masuda T, Kosaka T, Nakamura K, Hongo H, Yuge K, Nishihara H, Oya M.
    BMC Med Genomics. 2022 May 21;15(1):118. doi: 10.1186/s12920-022-01267-z.
  • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M.
    BMC Med Genomics. 2022 Jun 20;15(1):138. doi: 10.1186/s12920-022-01286-w.
  • A low subcutaneous fat mass is a risk factor for the development of inguinal hernia after radical prostatectomy.
    Umeda K, Takeda T, Hakozaki K, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M.
    Langenbecks Arch Surg. 2022 Nov;407(7):3107-3112. doi: 10.1007/s00423-022-02526-4. Epub 2022 Jun 21.
  • Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations.
    Kamisawa K, Kosaka T, Nakamura K, Yasumizu Y, Hongo H, Takeda T, Matsumoto K, Nishihara H, Oya M.
    Cancer Sci. 2022 Sep;113(9):3161-3168. doi: 10.1111/cas.15473. Epub 2022 Jul 18.
  • Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma.
    Kufukihara R, Tanaka N, Takamatsu K, Niwa N, Fukumoto K, Yasumizu Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Aimono E, Nishihara H, Mizuno R, Oya M.
    Br J Cancer. 2022 Oct;127(6):1133-1141. doi: 10.1038/s41416-022-01895-3. Epub 2022 Jun 28.
  • Salvage focal brachytherapy in castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy.
    Komori T, Kosaka T, Watanabe K, Tanaka T, Yasumizu Y, Hongo H, Mikami S, Ohashi T, Oya M.
    IJU Case Rep. 2022 Apr 28;5(4):233-236. doi: 10.1002/iju5.12442. eCollection 2022 Jul.
  • Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell Resolution.
    Iwahashi N, Umakoshi H, Seki T, Gomez-Sanchez CE, Mukai K, Suematsu M, Umezawa Y, Oya M, Kosaka T, Seki M, Suzuki Y, Horiuchi Y, Ogawa Y, Nishimoto K.
    J Clin Endocrinol Metab. 2022 Aug 18;107(9):2439-2448. doi: 10.1210/clinem/dgac394.
  • Functional analysis of GCNT3 for cell migration and EMT of castration-resistant prostate cancer cells.
    Yamamoto D, Sasaki K, Kosaka T, Oya M, Sato T.
    Glycobiology. 2022 Sep 19;32(10):897-908. doi: 10.1093/glycob/cwac044.
  • Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.
    Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, Kakehi Y, Nonomura N, Ogawa O, Oya M, Suzuki K, Saito A, Asakawa K, Uno S, Naito S.
    Int J Clin Oncol. 2022 Oct;27(10):1632-1643. doi: 10.1007/s10147-022-02221-w. Epub 2022 Aug 10.
  • Predictors of renal function after adrenalectomy in patients with Cushing or subclinical Cushing syndrome.
    Kufukihara R, Takeda T, Hakozaki K, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Miyashita K, Kurihara I, Oya M.
    Int J Urol. 2022 Dec;29(12):1447-1454. doi: 10.1111/iju.15007. Epub 2022 Aug 24.
  • Site-Specific Differences in PD-1 Blockade Success and Biomarkers in Urothelial Carcinoma Treated with Pembrolizumab.
    Umeda K, Tanaka N, Yasumizu Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Mizuno R, Oya M.
    Clin Genitourin Cancer. 2023 Feb;21(1):128-135. doi: 10.1016/j.clgc.2022.08.004. Epub 2022 Aug 7.
  • Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient.
    Kaneko Y, Kosaka T, Nakamura K, Mikami S, Nishihara H, Oya M.
    IJU Case Rep. 2022 Jun 24;5(5):323-326. doi: 10.1002/iju5.12466. eCollection 2022 Sep.
  • Evaluation of prognostic factors and treatment options for renal angiosarcoma: A retrospective analysis of 113 reported cases.
    Kamitani R, Matsumoto K, Takeda T, Mizuno R, Oya M.
    Eur J Surg Oncol. 2023 Jan;49(1):263-270. doi: 10.1016/j.ejso.2022.09.001. Epub 2022 Sep 8.
  • Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
    Iwasawa T, Kosaka T, Yasumizu Y, Hongo H, Yanai Y, Baba Y, Matsumoto K, Nakamura K, Nishihara H, Oya M.
    Int J Clin Oncol. 2022 Dec;27(12):1867-1873. doi: 10.1007/s10147-022-02248-z. Epub 2022 Oct 21.
  • The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
    Uemura H, Oya M, Kamoto T, Sugimoto M, Shinozaki K, Morita K, Koto R, Takahashi M, Nii M, Shin E, Nonomura N.
    Cancer Med. 2023 Mar;12(5):5265-5274. doi: 10.1002/cam4.5333. Epub 2022 Nov 10.
  • Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer.
    Arai M, Kosaka T, Yasumizu Y, Takeda T, Matsumoto K, Oya M.
    Int J Urol. 2023 Feb;30(2):235-239. doi: 10.1111/iju.15098. Epub 2022 Nov 14.
  • The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation.
    Hongo H, Kosaka T, Nakamura K, Mikami S, Nishihara H, Oya M.
    Asian J Urol. 2022 Oct;9(4):480-482. doi: 10.1016/j.ajur.2022.02.002. Epub 2022 Feb 20.
  • Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.
    Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Perini R, Yusa W, Ikezawa H, Narita T, Tomita Y.
    Cancer Med. 2022 Dec 1. doi: 10.1002/cam4.5483. Online ahead of print.
  • IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
    Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N.
    BMC Cancer. 2022 Dec 9;22(1):1292. doi: 10.1186/s12885-022-10398-6.
  • Current clinical perspective of urological oncology in the adolescent and young adult generation.
    Takahashi R, Asanuma H, Mizuno R, Oya M.
    Int J Clin Oncol. 2023 Jan;28(1):28-40. doi: 10.1007/s10147-022-02251-4. Epub 2022 Dec 17.
  • Genomic analysis of aggressive ductal adenocarcinoma of the prostate.
    Kobayashi H, Kosaka T, Nakamura K, Kimura T, Nishihara H, Oya M.
    Cancer Med. 2022 Dec 26. doi: 10.1002/cam4.5573. Online ahead of print.
  • Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
    Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, Choueiri TK.
    Oncologist. 2022 Dec 28:oyac243. doi: 10.1093/oncolo/oyac243. Online ahead of print.
  • Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
    Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, Arai G, Matsubara N, Yasumizu Y, Kosaka T, Oya M, Sugimoto M.
    Transl Androl Urol. 2022 Dec;11(12):1771-1785. doi: 10.21037/tau-22-396.